Product Description
Alocelyvir is being developed for the treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04758533?term=Alocelyvir&draw=2&rank=1)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Medulloblastoma|Uveal Melanoma|Glioma
Phase 1: Oncology Solid Tumor Unspecified|Medulloblastoma|Glioma|Epilepsy|Encephalitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-518417-25-00 |
FIBHNJ-2019-01 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2028-09-30 |
2025-05-02 |
Treatments |
|
2024-520427-86-00 |
Rasmusscell | P1 |
Not yet recruiting |
Epilepsy|Encephalitis |
2027-12-31 |
2025-05-02 |
Treatments |
|
2022-502516-37-00 |
FIBHNJ-2020-01 | P1 |
Active, not recruiting |
Medulloblastoma|Glioma |
2025-07-01 |
2025-05-02 |
Treatments |
|
2020-004838-37 |
FIBHNJ-2020-01 | P1 |
Active, not recruiting |
Medulloblastoma|Glioma |
2025-02-23 |
12% |
||
2019-001154-26 |
FIBHNJ-2019-01 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2023-07-23 |
2025-06-28 |
Treatments |
|
NCT04758533 |
AloCELYVIR | P2 |
Active, not recruiting |
Glioma|Medulloblastoma |
2026-04-01 |
12% |
2024-08-29 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
2024-515032-76-00 |
2024-515032-76-00 | P2 |
Recruiting |
Uveal Melanoma |
2025-12-01 |
2025-05-02 |
Treatments |
|
NCT05047276 |
PULSE-UM | P2 |
Unknown status |
Uveal Melanoma |
2023-06-30 |
2025-01-03 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|